The 53 references in paper A. Smirnov V., M. Volkov M., А. Смирнов В., М. Волков М. (2008) “РОЛЬ ВИТАМИНА D В ЗАМЕДЛЕНИИ ПРОГРЕССИРОВАНИЯ ХРОНИЧЕСКОЙ БОЛЕЗНИ ПОЧЕК // THE ROLE OF VITAMIN D IN PROGRESSION OF CHRONIC KIDNEY DISEASE” / spz:neicon:nefr:y:2008:i:4:p:20-27

1
Tian J, Liu X Williams LA, de Zeeuw D. Potential role of active vitamin D in retarding the progression of chronic kidney disease. Nephrol Dial Transplant 2007;22(2):321-328
(check this in PDF content)
2
Levin A, Bakris GL, Molitch M et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007;71(1):31-38
(check this in PDF content)
3
Haussler MR, Whitfield GK, Haussler CA et al. The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J Bone Miner Res 1998;13(3):325-349
(check this in PDF content)
4
O’Connell TD, Simpson RU. Immunochemical identification of the 1,25-dihydroxyvitamin D3 receptor protein in human heart. Cell Biol Int 1996;20(9):621-624
(check this in PDF content)
5
Sandgren ME, Bronnegard M, DeLuca HF. Tissue distribution of the 1,25-dihydroxyvitamin D3 receptor in the male rat. Biochem Biophys Res Commun 1991 16;181(2):611-616
(check this in PDF content)
6
Kovesdy CP, Kalantar-Zadeh K. Vitamin D receptor activation and survival in chronic kidney disease. Kidney Int 2008; 73(12):1355-1363
(check this in PDF content)
7
Hughson MD, Johnson K, Young RJ et al. Glomerular size and glomerulosclerosis: relationships to disease categories, glomerular solidification, and ischemic obsolescence. Am J Kidney Dis 2002;39(4):679-688.
(check this in PDF content)
8
Abdi R, Dong VM, Rubel JR et al. Correlation between glomerular size and long-term renal function in patients with substantial loss of renal mass. J Urol 2003;170(1):42-44.
(check this in PDF content)
9
Schwarz U, Amann K, Orth SR et al. Effect of 1,25(OH)2 vitamin D3 on glomerulosclerosis in subtotally nephrectomized rats. Effect of 1,25(OH)2 vitamin D3 on glomerulosclerosis in subtotally nephrectomized rats. Kidney Int 1998;53(6):1696- 1705
(check this in PDF content)
10
Hirata M, Makibayashi K, Katsumata K et al. 22- Oxacalcitriol prevents progressive glomerulosclerosis without adversely affecting calcium and phosphorus metabolism in subtotally nephrectomized rats. Nephrol Dial Transplant 2002;17(12):2132-2137
(check this in PDF content)
11
Li YC, Kong J, Wei M et al. 1,25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002; 110:229-238
(check this in PDF content)
12
Li YC. Vitamin D regulation of the renin-angiotensin system. J Cell Biochem 2003;88(2):327-331
(check this in PDF content)
13
Weinreich T, Merke J, Schonermark M et al. Actions of 1.25- dihydroxyvitamin D3 on human mesangial cells. Am J Kidney Dis 1991;18(3):359-366
(check this in PDF content)
14
Panichi V, Migliori M, Taccola D et al. Effects of 1,25(OH)2D3 in experimental mesangial proliferative nephritis in rats. Kidney Int 2001;60(1):87-95
(check this in PDF content)
15
Makibayashi K, Tatematsu M, Hirata M et al. A vitamin D analog ameliorates glomerular injury on rat glomerulonephritis. Am J Pathol 2001;158(5):1733-1741
(check this in PDF content)
16
Kuhlmann A, Haas CS, Gross ML et al. 1,25- Dihydroxyvitamin D3 decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat. Am J Physiol Renal Physiol 2004;286(3):F526-533
(check this in PDF content)
17
Agarwal R, Acharya M, Tian J et al. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int 2005;68(6):2823-2828
(check this in PDF content)
18
Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med 1998;339(20):1448-1456
(check this in PDF content)
19
Segerer S, Nelson PJ, Schlondorff D. Chemokines, chemokine receptors, and renal disease: from basic science to pathophysiologic and therapeutic studies. J Am Soc Nephrol
(check this in PDF content)
20
0;11(1):152-176 20. Provvedini DM, Tsoukas CD, Deftos LJ, Manolagas SC. 1.25- dihydroxyvitamin D3 receptors in human leukocytes. Science 1983;221(4616):1181-1183
(check this in PDF content)
21
Veldman CM, Cantorna MT, DeLuca HF. Expression of 1.25- dihydroxyvitamin D(3) receptor in the immune system. Arch Biochem Biophys 2000 15;374(2):334-338
(check this in PDF content)
22
Guijarro C, Egido J. Transcription factor-kappa B (NF- kappa B) and renal disease. Kidney Int 2001;59(2):415-424
(check this in PDF content)
23
Yu XP, Bellido T, Manolagas SC. Down-regulation of NF- kappa B protein levels in activated human lymphocytes by 1,25- dihydroxyvitamin D3. Proc Natl Acad Sci USA 1995; 92(24):10990-10994
(check this in PDF content)
24
Xing N, L Maldonado ML, Bachman LA et al. Distinctive dendritic cell modulation by vitamin D(3) and glucocorticoid pathways. Biochem Biophys Res Commun 2002;297(3):645- 652
(check this in PDF content)
25
Panichi V, De Pietro S, Andreini B et al. Calcitriol modulates in vivo and in vitro cytokine production: a role for intracellular calcium. Kidney Int 1998;54(5):1463-1469
(check this in PDF content)
26
Boonstra A, Barrat FJ, Crain C et al. 1alpha,25- Dihydroxyvitamin d3 has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells. J Immunol 2001;167(9):4974-4980
(check this in PDF content)
27
Mathieu C, Adorini L. The coming of age of 1,25- dihydroxyvitamin D(3) analogs as immunomodulatory agents. Trends Mol Med 2002;8(4):174-179
(check this in PDF content)
28
Lemire JM, Ince A, Takashima M. 1,25-Dihydroxyvitamin D3 attenuates the expression of experimental murine lupus of MRL/l mice. Autoimmunity 1992;12(2):143-148
(check this in PDF content)
29
Branisteanu DD, Leenaerts P, van Damme B, Bouillon R. Partial prevention of active Heymann nephritis by 1 alpha, 25 dihydroxyvitamin D3. Clin Exp Immunol 1993;94(3):412-417
(check this in PDF content)
30
Zehnder D, Bland R, Williams MC et al. Extrarenal expression of 25-hydroxyvitamin d(3)-1 alpha-hydroxylase. J Clin Endocrinol Metab 2001;86(2):888-894
(check this in PDF content)
31
Moe SM, Zekonis M, Harezlak J et al. A placebo- controlled trial to evaluate immunomodulatory effects of paricalcitol. Am J Kidney Dis 2001;38(4):792-802
(check this in PDF content)
32
Takemoto F, Shinki T, Yokoyama K et al. Gene expression of vitamin D hydroxylase and megalin in the remnant kidney of nephrectomized rats. Kidney Int 2003;64(2):414-420
(check this in PDF content)
33
Healy KD, Frahm MA, DeLuca HF. 1,25-Dihydroxyvitamin D3 up-regulates the renal vitamin D receptor through indirect gene activation and receptor stabilization. Arch Biochem Biophys 2005;433(2):466-473
(check this in PDF content)
34
Gekle M. Renal tubule albumin transport. Annu Rev Physiol 2005;67:573-594
(check this in PDF content)
35
Weinreich T, Muller A, Wuthrich RP et al. 1,25- dihydroxyvitamin D3 and the synthetic vitamin D analogue, KH 1060, modulate the growth of mouse proximal tubular cells. Kidney Blood Press Res 1996;19(6):325-331
(check this in PDF content)
36
Li Y Spataro BC, Yang J et al. 1,25-dihydroxyvitamin D inhibits renal interstitial myofibroblast activation by inducing hepatocyte growth factor expression. Kidney Int 2005;68(4):1500- 1510
(check this in PDF content)
37
Palmer HG, Gonzalez-Sancho JM, Espada J et al. Vitamin D(3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta- catenin signaling. J Cell Biol 2001 Jul 23;154(2):369-387
(check this in PDF content)
38
Yanagisawa J, Yanagi Y Masuhiro Y et al. Convergence of transforming growth factor-beta and vitamin D signaling pathways on SMAD transcriptional coactivators. Science 1999; 283(5406):1317-1321
(check this in PDF content)
39
Aschenbrenner JK, Sollinger HW, Becker BN, Hullett DA. 1,25-(OH)2D3 alters the transforming growth factor beta signaling pathway in renal tissue. J Surg Res 2001;100(2):171- 175
(check this in PDF content)
40
Liu Y. Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. J Am Soc Nephrol 2004;15(1):1- 12
(check this in PDF content)
41
Li X Yang J, Dai C et al. Role for integrin-linked kinase in mediating tubular epithelial to mesenchymal transition and renal interstitial fibrogenesis. J Clin Invest 2003;112(4):503- 516
(check this in PDF content)
42
Tan X, Li X Liu Y Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy. J Am Soc Nephrol 2006;17(12):3382-3393
(check this in PDF content)
43
Aihara K, Azuma H, Akaike M et al. Disruption of nuclear vitamin D receptor gene causes enhanced thrombogenicity in mice. J Biol Chem 2004;279(34):35798-35802
(check this in PDF content)
44
Li X, Zheng W, Li YC. Altered gene expression profile in the kidney of vitamin D receptor knockout mice. J Cell Biochem 2003;89(4):709-719
(check this in PDF content)
45
Tougaard L, Sorensen E, Brochner-Mortensen J et al. Controlled trial of 1apha-hydroxycholecalciferol in chronic renal failure. Lancet 1976;1(7968):1044-1047
(check this in PDF content)
46
Christiansen C, Rodbro P, Christensen MS et al. Deterioration of renal function during treatment of chronic renal failure with 1,25-dihydroxycholecalciferol. Lancet 1978;2(8092 Pt 1):700-703
(check this in PDF content)
47
Hamdy NA, Kanis JA, Beneton MN et al. Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ 1995;310(6976):358-363
(check this in PDF content)
48
Coburn JW, Maung HM, Elangovan L et al. Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4. Am J Kidney Dis 2004;43(5):877-890
(check this in PDF content)
49
Ritz E, Kuster S, Schmidt-Gayk H et al. Low-dose calcitriol prevents the rise in 1,84-iPTH without affecting serum calcium and phosphate in patients with moderate renal failure (prospective placebo-controlled multicentre trial). Nephrol Dial Transplant 1995;10(12):2228-2234
(check this in PDF content)
50
Rix M, Eskildsen P, Olgaard K. Effect of 18 months of treatment with alfacalcidol on bone in patients with mild to moderate chronic renal failure. Nephrol Dial Transplant 2004;19(4):870-876
(check this in PDF content)
51
O’Herrin JK, Hullett DA, Heisey DM et al. A retrospective evaluation of 1,25-dihydroxyvitamin D(3) and its potential effects on renal allograft function. Am J Nephrol 2002;22(5-6):515-520
(check this in PDF content)
52
Zeeuw D, Remuzzi G, Parving HH et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004;65(6):2309- 2320
(check this in PDF content)
53
Zeeuw D, Remuzzi G, Parving HH et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004;110(8):921- 927 Поступила в редакцию 09.09.2008 г.
(check this in PDF content)